FDA Loosens Reins on Crisis Lab Tests for Speed
Published Date: 9/23/2025
Notice
Summary
The FDA just released new rules about how they’ll handle certain lab tests during emergencies, like a health crisis. If you make or use these tests, this guidance explains when the FDA might relax some rules to help get tests out faster. This means quicker access to important tests without waiting for all the usual approvals, saving time and possibly money during emergencies.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA may relax rules for IVD makers
The FDA guidance explains the factors it will use to decide whether to issue an enforcement policy that allows manufacturers to offer certain unapproved in vitro diagnostic (IVD) tests or unapproved uses of approved IVD tests during a Section 564 declared emergency. If the FDA issues such an enforcement policy, makers could be allowed to provide tests without completing the usual approvals during that declared emergency.
Faster access to certain tests in emergencies
During a Section 564 declared emergency, the FDA may issue enforcement policies that allow certain unapproved IVD tests or unapproved uses of approved tests to be offered. You could get access to some lab tests sooner in that declared emergency because the guidance explains when the FDA might permit those offerings.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-18401, Multilayered Wood Flooring From the People's Republic of China: Notice of Court Decision Not in Harmony With the Results of Countervailing Duty Administrative Review; Notice of Amended Final Results
The U.S. Court of International Trade made a final decision about taxes on multilayered wood flooring from China for 2017. Because of this, the Department of Commerce is changing the subsidy rates (extra fees) for some companies like Jiangsu Senmao and Riverside Plywood, but not for Jiangsu Guyu. If you’re involved with these companies or import this flooring, expect updated fees and official changes soon.
Next: 2025-18404, Evaluation of the Georgia Coastal Management Program; Notice of Public Meeting; Request for Comments
NOAA is checking how well Georgia’s Coastal Management Program is working and wants your thoughts! If you live near Georgia’s coast or care about protecting it, now’s your chance to join a virtual meeting or send in comments. This review could shape future plans and funding to keep Georgia’s coast safe and beautiful.